

Press Release

July 4, 2017
EFPIA Japan

EFPIA Japan launches patient organization support program PASE - JPY 1 million annual grants for patient organization activities -

EFPIA Japan (Chairman: Ole Mølskov Bech) announces today the launch of its patient organization support program “PASE” (Patient Advocacy Support by EFPIA Japan). The aim of the program is to further encourage and promote the activities of Japanese patient organizations. Through PASE, EFPIA Japan will contribute grants of 1 million yen annually with the aim of achieving a more patient-centric healthcare system in Japan.

PASE aims to provide a voice for patients to the health community by strengthening patient organization activities. Grants provided are intended to fund valuable projects that will help achieve a more patient-centric healthcare system. Funding is available to patient organizations whose activities target Japanese patients and who are officially registered not-for-profit organizations, such as incorporated associations, foundations, and NPOs. Eligible organizations are encouraged to apply before the deadline by outlining their intended activities, objectives, and execution plans that could be funded with the aid of an EFPIA PASE grant. Selected patient organizations will be presented with the grants at an awards ceremony during EFPIA Day, which is scheduled for 1 November 2017. For details on the PASE grant selection criteria and application procedures, please refer to the EFPIA Japan home page:

http://www.efpia.jp/link/1706_Notifcation_EFPIA_PASE_EN.pdf.

“The goal for all of EFPIA Japan’s activities is to foster a healthcare system that benefits patients,” said Ole Mølskov Bech, EFPIA Chairman. “To improve health outcomes in Japan, it’s important for all patients to deepen their understanding of disease burden and treatment options. It’s also critical for their opinions to be reflected in the health system. EFPIA Japan hopes that PASE will play an important role for patient groups in shaping a more patient-centric health environment in Japan.”

###

About EFPIA Japan:

Established in 2002, EFPIA Japan represents 24 R&D-based European pharmaceutical companies operating in Japan. In 2015, combined sales from the member companies accounted for roughly 25% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About European Federation of Pharmaceutical Industries and Associations (EFPIA):

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

For more information please visit:

<http://efpia.jp/English/index-e.html> (EFPIA Japan)
<http://www.efpia.eu> (EFPIA)

Contact:

Noriko Okazaki, Chair of EFPIA Japan Public Relations Committee

2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005
Novo Nordisk Pharma Ltd.
TEL: 03-6266-1700
Mail: no@novonordisk.com

Tetsu Owari, Vice Chair of EFPIA Japan Public Relations Committee

ThinkPark Tower 2-1-1 Osaki, Shinagawa-ku, Tokyo 141-6017
Boehringer Ingelheim Japan, Inc.
TEL: 03-6417-2223
Mail: tetsuya.owari@boehringer-ingelheim.com

###